Bone loss during oestriol therapy in postmenopausal women.
In contrast to all other oestrogens examined thus far oestriol hemisuccinate (12 mg/day) did not prevent bone loss in 28 postmenopausal women. The average bone loss, however, was somewhat less than expected from placebo studies, while the bone loss achieved by a group taking 4-6 mg/day was equal to that achieved by previous placebo groups. To be an effective agent for prevention of post-menopausal osteoporosis oestriol would have to be prescribed in daily doses considerably in excess of 12 mg.
D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood; D001842:Bone and Bones / Q000187:drug effects*; D002118:Calcium / Q000097:blood / Q000378:metabolism; D002986:Clinical Trials as Topic; D003401:Creatine / Q000652:urine; D004311:Double-Blind Method; D004601:Elementary Particles; D004964:Estriol / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D008593:Menopause / Q000187:drug effects*; D008875:Middle Aged; D010024:Osteoporosis / Q000517:prevention & control*; D010710:Phosphates / Q000097:blood; D010919:Placebos; D013054:Spectrophotometry, Atomic
D010710:Phosphates; D010919:Placebos; D000469:Alkaline Phosphatase; D004964:Estriol; D003401:Creatine; D006909:Hydroxyproline; D002118:Calcium